Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

×



Make an Appointment

Tangible Materials Available for Licensing

Materials Available for Licensing

Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

<u>History</u>

Equality, diversity & inclusion

Annual report

Give to MSK

I his cell line was established in 1974 from a metastatic site (axillary lymph node) in a 24-year-old Caucasian female with malignant melanoma.

Inventors

Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research

Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

Carey TE et al. (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. *Proceedings of the National Academy of Sciences* 73: 3278-3282 (PubMed ID: 1067619)

Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. *Oncogene* 31(4):446-457 (PubMed ID: 21725359)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

•

Commercial License: Contact MSK's Tangible Materials team at TRMOTDRTM@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, <u>646-888-2354</u>, <u>weisgarf@mskcc.org</u>.

Stage of Development

Ready to use

Indications

Cancer > Melanoma

Types

Research Tools > Cell Lines



Find a doctor

Research & Education

Sloan Kettering Institute

Gerstner Sloan Kettering Graduate School

Graduate medical education

MSK Library

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility statement

Privacy policy

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center